Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Rhea-AI Summary
Oncolytics Biotech will host a conference call and webcast on Tuesday, November 12, 2024, at 8:30 a.m. ET to discuss its third-quarter 2024 financial results and recent operational highlights. The event will be accessible via North American toll-free number (888) 510-2154 and international number (437) 900-0527. Participants can also join through RapidConnect or access the webcast on the Investor Relations page of Oncolytics' website. The webcast will be archived for three months, with a dial-in replay available for one week at (888) 660-6345 (North America) or (289) 819-1450 (International) using replay code 68336#.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ONCY gained 0.93%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call and webcast to take place on Tuesday, November 12, 2024, at 8:30 a.m. ET
Conference Call & Webcast
Date: Tuesday, November 12, 2024
Time: 8:30 a.m. ET
Dial In – North American Toll-Free: (888) 510-2154
Dial In – International: (437) 900-0527
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 68336
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact Jon Patton Director of IR & Communication jpatton@oncolytics.ca | Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 |
Logo - https://mma.prnewswire.com/media/2408622/Oncolytics_Biotech_Inc_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and-recent-operational-highlights-302301016.html
SOURCE Oncolytics Biotech® Inc.
FAQ
When is Oncolytics Biotech's conference call to discuss Q3 2024 financial results?
How can I access Oncolytics Biotech's Q3 2024 financial results webcast?
What is the dial-in number for Oncolytics Biotech's Q3 2024 financial results call?
How long will the webcast of Oncolytics Biotech's Q3 2024 financial results be available?
What is the replay code for Oncolytics Biotech's Q3 2024 financial results call?
